v3.26.3
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Revenues      
Sales of goods $ 0 $ 0 $ 0
Total revenue 0 0 0
Cost of goods sold and operating Expenses      
Cost of goods sold 0 0 0
Research and development 1,482 3,280 3,994
General and administrative 2,195 1,003 4,356
Total operating expenses 3,677 4,283 8,350
Loss from operations (3,677) (4,283) (8,350)
Other income (expense)      
Loss on conversion of debt     440
Other income 0 0 0
Finance income (11) 17 7
Finance costs (587) (226) (58)
Operating lease interest expense 0 0 3
Loss before income taxes (4,275) (4,492) (8,844)
Income tax provision (recovery) 0 0 0
Net loss (4,275) (4,492) (8,844)
Net loss attributable to Nymox shareholders $ (4,275) $ (4,492) $ (8,844)
Basic and diluted loss per share $ (0.05) $ (0.05) $ (0.10)
Weighted average number of common shares outstanding 96,040 93,671 91,687